24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

re subjects discontinued LPV/r due to AEs (6 percent) than 908/rQD or 908/r BID (both <1 percent).

Likewise, Grade 3-4 lab abnormalities were similar between all three treatment arms, and all regimens had minimal impact on plasma lipids. The incidence of Grade 3-4 lipid abnormalities was low. No subject experienced a Grade 3-4 elevation in cholesterol, whereas elevated triglyceride levels occurred in 8 percent of patients taking 908/r BID (n=8,) versus 4 percent of patients taking 908/r QD (n=4) or LPV/r BID (n=4). Mean fasting cholesterol levels for all three study groups remained below the recommended National Cholesterol Education Program (NCEP) intervention guidelines.

Study Demographics

The study population comprised patients enrolled from 103 centers in 13 countries worldwide. Approximately 16 percent of patients enrolled in CONTEXT are female, and the age range of all patients is 24 72 years (median 41 years). Sixty-seven percent of patients are Caucasian, 24 percent are of African descent and 9 percent are Hispanic. Criteria for entry into the study included treatment-experienced patients with current failure of antiretroviral therapy. To enroll in the CONTEXT trial, patients had to have a screening viral load >1,000 copies/mL and no active or acute Category C events (indicative of AIDS disease) according to guidelines established by the Centers for Disease Control and Prevention.

Summary of Clinical Trials with 908

More than 1,200 people have participated in three Phase III trials to test the safety and efficacy of 908: NEAT, SOLO and CONTEXT. The SOLO study was an open-label trial with 649 HIV+, treatment-nave patients. Participants were randomized to receive either 1400 mg of 908 plus 200 mg ritonavir (908/r) QD or 1250 mg of nelfinavir BID. All also received the two NRTIs, ABC and 3TC. The trial, conducted at more than 100 research centers worldwide, was designed to assess the safety and efficacy of each

Contact: Amy Kling
Public Communications Inc.

Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:

(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
Breaking Biology Technology:
Cached News: